8SILVERMAN E, IN K H, YANDAVA C, et al. Pharmacogentics of the 5-lipoxygenase pathway in asthma[ J ]. Clin Exp Allergy, 1998,28 ( Suppl 5 ) : 164 - 170.
4Eiselt R,Domanski TL,Zibat A,et al. Identification and functional characterization of eight CYP3A4 protein variants [J]. Pharmacogenetic,2001,1(5):47.
5Sata F,Sapone A,Elizondo G,et al. CYP3A4 allelic variants with amino acid substitutions in axons 7 and 12:0 evidence for an allelic variant with altered catalytic activity[J]. Clin Pharmacol Ther ,000,67(1):8.
6Felix CA,Walker AH,Lange BJ,et al. Association of CYP3A4 genotype with treatment related leukemia [J]. Proc Natl Acad Sci USA,1998,5:3176.
7Harinder SM,Karen LG. Atorvastatin an updated review of its pharmacological properties and use in dyslipidaemia[J]. Drugs,2001,1(12):1835.
8Gonzalez F,Skoda RC,Kimura S,et al. Characterization of the common genetic defect in humans in debrisoquine metabolism [J].Nature,1988,31:442.
9Mulder AB,Van Lijf HJ,Bon MA,et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin [J]. Clin Pharmacol Ther,2001,0(6):546.
10Geisel J. The efficacy of simvastatin is not influenced by CYP2D6 polymorphism[J]. Clin Pharmacol Ther ,2002,0(11):95.
